|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TISSUE-SPECIFIC STEM CELLS |
aMonash Immunology and Stem Cell Laboratories, Monash University, Melbourne, Victoria, Australia;
bDepartment of Anatomy and Cell Biology, Monash University, Victoria, Australia
Key Words. Bone marrow-derived progenitor cells • Myofibroblasts • Endothelial cells • p38 mitogen-activated protein kinase • Smad Renal fibrosis
Correspondence: Sharon D. Ricardo, Ph.D., Monash Immunology and Stem Cell Laboratories (MISCL), Monash University, Clayton, Victoria 3800, Australia. Telephone: 61 3 9905 0671; Fax: 61 3 9905 0680; e-mail: Sharon.ricardo{at}med.monash.edu.au
Received on March 7, 2006;
accepted for publication on November 28, 2006.
First published online in STEM CELLS EXPRESS December 14, 2006.
Recent evidence suggests that bone marrow (BM)-derived cells may integrate into the kidney, giving rise to functional renal cell types, including endothelial and epithelial cells and myofibroblasts. BM-derived cells can contribute to repair of the renal peritubular capillary (PTC) network following acute ischemic injury. However, the cell fate and regulation of BM-derived cells during the progression of chronic renal disease remains unclear. Using chimeric mice transplanted with enhanced green fluorescent protein (EGFP)-expressing BM, we demonstrate that the number of BM-derived myofibroblasts coincided with the development of fibrosis in a mouse adriamycin (ADR)-induced nephrosis model of chronic, progressive renal fibrosis. Four weeks after ADR injection, increased numbers of BM-derived myofibroblasts were observed in the interstitium of ADR-injected mice. Six weeks after ADR injection, more than 30% of renal
-smooth muscle actin (+) (
-SMA+) interstitial myofibroblasts were derived from the BM. In addition, BM-derived cells were observed to express the endothelial cell marker CD31 and the myofibroblast marker
-SMA. Blockade of p38 mitogen-activated protein kinase (MAPK) and transforming growth factor (TGF)-β1/Smad2 signaling was found to protect BM-derived PTC endothelial cells and inhibit the number of BM-derived von Willebrand factor (vWF)(+)/EGFP(+)/
-SMA(+) cells, EGFP(+)/
-SMA(+) cells, and total
-SMA(+) cells in ADR-injected mice. Inhibition of the p38 MAPK and TGF-β1/Smad signaling pathways enhanced PTC repair by decreasing endothelial-myofibroblast transformation, leading to structural and functional renal recovery and the attenuation of renal interstitial fibrosis. Investigation of the signaling pathways that regulate the differentiation and survival of BM-derived cells in a progressive disease setting is vital for the successful development of cell-based therapies for renal repair.
This article has been cited by other articles:
![]() |
T. D. Hewitson Renal tubulointerstitial fibrosis: common but never simple Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1239 - F1244. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |